**Core Concept**
Ticagrelor is a potent and reversible P2Y12 receptor antagonist used to inhibit platelet aggregation. It is a member of the cyclopentyltriazolopyrimidine class of antiplatelet agents.

**Why the Correct Answer is Right**
Ticagrelor works by blocking the P2Y12 receptor on platelet cell membranes, which is responsible for inhibiting the binding of adenosine diphosphate (ADP) to its receptor. This action results in reduced platelet activation and aggregation, thereby reducing the risk of thrombotic events such as myocardial infarction. Ticagrelor is often used in combination with acetylsalicylic acid (aspirin) to further reduce the risk of cardiovascular events.

**Why Each Wrong Option is Incorrect**
**Option A:** Ticagrelor is not a beta-blocker, which are a different class of antianginal medications.
**Option B:** Ticagrelor is not an angiotensin-converting enzyme (ACE) inhibitor, which are used to treat hypertension and heart failure.
**Option C:** Ticagrelor is not a statin, which are used to lower cholesterol levels and prevent cardiovascular disease.

**Clinical Pearl / High-Yield Fact**
Ticagrelor is known to cause dyspnea as a side effect due to its effects on potassium channels and increased cyclic AMP levels in the lungs, which can lead to a sensation of shortness of breath.

**Correct Answer:** A. Ticagrelor is used to inhibit platelet aggregation and prevent thrombotic events.